Fingerprint
Dive into the research topics of 'Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically